VI 1121

Drug Profile

VI 1121

Alternative Names: VI-1121

Latest Information Update: 31 Aug 2015

Price : $50

At a glance

  • Originator VIVUS
  • Class Antidementias
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 31 Aug 2015 Discontinued - Phase-II for Alzheimer's disease (Adjunctive treatment) in USA (unspecified route)
  • 31 Aug 2013 VIVUS completes a phase II trial for Alzheimer's disease (adjunctive treatment) in USA (NCT01428362)
  • 05 Mar 2013 VIVUS completes enrolment in its phase II trial for Alzheimer's disease (adjunctive treatment) in USA (NCT01428362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top